Brought to you by 
Zhejiang Huahai gets exclusive rights to four biosimilars from Oncobiologics
01 Aug 2013
Executive Summary
Oncobiologics Inc. (cancer treaments and immunotherapies) has granted Shanghai-based drug company Zhejiang Huahai Pharmaceuticals Co. Ltd. rights to develop, manufacture, and sell four biosimilar monoclonal antibodies. Huahai gets exclusive rights in China (and will manufacture the products at its biologics facility there), and will co-develop and commercialize with Oncobiologics in more than 30 developed countries, including the US, EU, Japan, Australia, and Canada.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zhejiang Huahai gets exclusive rights to four biosimilars from Oncobiologics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice